fda glp-1 compounding crackdown news october 2025 Why the is cracking down on compound drugs for weight loss Non-Traditional Channels: The Compounded GLP-1

Glucagon-like peptide-1 (GLP-1) is a GI peptide that stimulates insulin secretion (similar to sulfonylureas)

Some patients abandon therapy after reaching their target weight, while others are forced to pause or switch treatments due to supply shortages

Ron Grisanti, D.C., D.A.B.C.O., D.A.C.B.N., M.S., DIANM, CFMP is the founder of Functional Medicine University and author of The Medical Detective Reports. Read his full bio ...

The FDA noted that it had received over 1000 reports of adverse events arising from compounded GLP-1 dosing errors and unapproved ingredients and suggested that such adverse events are likely underreported due to the limited application of federal regulations to state-licensed pharmacies

Learn about their experience.